Oral presentation to highlight Iomab-B's ability to significantly improve overall survival in patients with relapsed or refractory AML with a TP53 mutation

口头介绍，以突出Iomab-B显着提高TP53突变复发或难治性AML患者总体生存率的能力

Four presentations in total demonstrating the mutation agnostic efficacy potential of Iomab-B and Actimab-A in relapsed or refractory and elderly AML patients

共有四篇演讲证明了Iomab-B和Actimab-A在复发或难治性和老年AML患者中的突变不可知疗效潜力

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023.

2023年12月8日，纽约/PRNewswire/--Actinium Pharmaceuticals，Inc.（纽约证券交易所美国证券交易所：ATNM）（Actinium或该公司），靶向放射疗法开发的领导者，今天宣布，其Iomab-B和Actimab-A计划的临床数据将在2023年12月9日至12日在圣地亚哥举行的第65届美国血液学会年会和博览会（ASH）上进行四次演讲。

These include an oral presentation and two poster presentations detailing results from the completed and positive Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML) as well as one poster presentation of Phase 1b results from the novel Actimab-A + Venetoclax combination trial for r/r AML..

其中包括一份口头报告和两份海报报告，详细介绍了55岁及以上活动性复发或难治性急性髓细胞白血病（r/r AML）患者Iomab-B已完成且阳性的3期SIERRA试验的结果，以及一份海报介绍了r/r AML新型Actimab-A+Venetoclax联合试验的1b期结果。。

Sandesh Seth, Actinium's Chairman & CEO, said, 'We are particularly excited for this year's ASH as our four presentations will highlight the differentiated capabilities of Iomab-B and Actimab-A. Better treatment options and outcomes are needed in AML, particularly for elderly patients and those with relapsed or refractory disease who represent a majority of the population.

Actinium董事长兼首席执行官桑德什·塞思（SandeshSeth）表示，“我们对今年的ASH特别兴奋，因为我们的四场演讲将突出Iomab-B和Actimab-A的差异化能力。AML需要更好的治疗选择和结果，特别是对于老年患者以及代表大多数人群的复发或难治性疾病患者。

Our strong presence at ASH is indicative of the potential that our targeted radiotherapies have in the management of patients with difficult to treat AML. We are progressing toward BLA and MAA filings for Iomab-B as well as initiating a pivotal trial Actimab-A next year, which will be significant steps toward achieving our vision of transforming the treatment of AML with our highly differentiated therapies.'.

我们在ASH的强大表现表明，我们的靶向放射疗法在治疗难治性AML患者方面具有潜力。我们正在为Iomab-B提交BLA和MAA文件，并于明年启动关键的Actimab-a试验，这将是实现我们用高度分化的疗法改变AML治疗愿景的重要步骤。”。

Iomab-B and Actimab-A target CD45 and CD33, respectively, both of which are validated targets with significant expression on AML cells. As targeted radiotherapeutics, Iomab-B and Actimab-A have both demonstrated the ability to overcome genetic mutations, including TP53, producing high response rates and improving survival outcomes in patients with difficult to treat, high-risk r/r AML..

Iomab-B和Actimab-A分别靶向CD45和CD33，两者都是在AML细胞上具有显着表达的验证靶标。作为靶向放射治疗药物，Iomab-B和Actimab-A均已证明能够克服包括TP53在内的基因突变，从而产生高反应率并改善难以治疗的高风险r/r AML患者的生存结果。。

Details of Actinium's presentations at ASH are as follows:

Actinium在ASH上的详细介绍如下：

Iomab-B Oral Presentation

Iomab-B口头报告

Title: 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

标题：131I Apamistamab领导的异基因造血细胞移植可显着提高TP53突变的R/R AML患者的总体生存率

Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Novel Conditioning Regimens for Myeloid Malignancies Session Date: Sunday, December 10, 2023 Session Time: 9:30 AM - 11:00 AM Pacific Time Presentation Time: 9:30 AM Room: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19.

会话名称：721。同种异体移植：调理方案，植入和急性毒性：骨髓恶性肿瘤的新型调理方案会议日期：2023年12月10日星期日会议时间：太平洋时间上午9:30-11:00会议时间：上午9:30会议室：万豪马奎斯圣地亚哥码头，太平洋宴会厅沙龙18-19。

Iomab-B Poster Presentations

Iomab-B海报展示

Title: 131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

标题：131I Apamistamab有效地实现了R/R AML患者的持久反应，无论是否存在多种高危因素

Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I Session Date: Saturday, December 9, 2023 Presentation Time: 5:30 PM - 7:30 PM Pacific TimeLocation: San Diego Convention Center, Halls G-H

会话名称：721。异基因移植：调理方案，植入和急性毒性：海报I会议日期：2023年12月9日星期六演讲时间：下午5:30-7:30太平洋时间地点：圣地亚哥会议中心，G-H大厅

Title: High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

标题：在HCT之前使用131I Apamistamab进行高剂量靶向放射治疗，证明了R/R AML患者持久完全缓解的剂量反应

Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster IISession Date: Sunday, December 10, 2023Presentation Time: 6:00 PM - 8:00 PM Pacific TimeLocation: San Diego Convention Center, Halls G-H

会话名称：721。异基因移植：调理方案，植入和急性毒性：海报II会议日期：2023年12月10日星期日会议时间：下午6:00-晚上8:00太平洋时间地点：圣地亚哥会议中心，G-H大厅

Actimab-A Poster Presentation

Actimab-A海报展示

Title: Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

标题：林妥珠单抗-Ac225联合Venetoclax治疗复发/难治性AML的靶向放疗1期研究的最新结果

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster ISession Date: Saturday, December 9, 2023:Presentation Time: 5:30 PM-7:30 PMLocation: San Diego Convention Center, Halls G-H

会话名称：616。急性髓系白血病：研究疗法，不包括移植和细胞免疫疗法：海报发布日期：2023年12月9日星期六：发布时间：下午5:30-7:30地点：圣地亚哥会议中心，霍尔G-H

About Actinium Pharmaceuticals, Inc.

关于Actinium Pharmaceuticals，Inc。

Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia.

锕开发有针对性的放射疗法，以有意义地提高现有肿瘤治疗失败的人的生存率。骨髓移植前的诱导和调理剂Iomab-B（pre-BLA）和治疗药物Actimab-A（National Cancer Institute CRADA pivotal development path）已证明有潜力延长复发和难治性急性髓细胞白血病患者的生存结果。

Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and several internal programs in solid tumors.

Actinium计划推进Iomab-B治疗其他血癌，下一代调理候选Iomab ACT改善细胞和基因治疗结果。Actinium的技术平台是与Astellas Pharma合作实体瘤，AVEO Oncology/LG Chem Life Sciences合作HER3实体瘤以及实体瘤内部几个项目的基础。

Actinium holds more than 220 patents and patent applications..

锕拥有220多项专利和专利申请。。

For more information, please visit: https://www.actiniumpharma.com/

有关更多信息，请访问：https://www.actiniumpharma.com/

Forward-Looking Statements

前瞻性声明

This press release may contain projections or other 'forward-looking statements' within the meaning of the 'safe-harbor' provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update.

本新闻稿可能包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的关于公司未来事件或未来财务表现的预测或其他“前瞻性声明”，公司没有义务更新这些预测或声明。

These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the 'SEC'), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time..

这些声明基于管理层当前的预期，并受到可能导致实际结果与预期或估计的未来结果产生重大差异的风险和不确定性的影响，包括与初步研究结果相关的风险和不确定性，这些风险和不确定性与最终结果不同，对正在开发的药物的潜在市场的估计，临床试验，FDA和其他政府机构的行动、监管许可、对监管事项的回应、市场对锕产品和服务的需求和接受程度、临床研究组织的表现以及锕提交给证券交易委员会（“SEC”）的文件中不时详述的其他风险，包括但不限于表10-K中的最新年度报告、表10-Q和表8-K中的后续季度报告，每一份报告都会不时修订和补充。。

Investors:[email protected]

投资者：[受电子邮件保护]

SOURCE Actinium Pharmaceuticals, Inc.

来源Actinium Pharmaceuticals，Inc。